Vemurafenib and TIL Therapy for Metastatic Melanoma

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticcarcinomacellmelanomatherapy
  Phrases that lowered it: evaluatepatients withclinicalefficacyday
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 29.4% (raises risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 97.3% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 47771 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 3 (raises risk) · Sponsor's track record
• Keywords listed: 0 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma NCT01659151 · started 2012 · scored riskier than 99% of active trials completed
• Peginterferon and TIL Therapy for Metastatic Melanoma NCT02379195 · started 2014 · scored riskier than 88% of active trials completed
• Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma NCT01883323 · started 2013 · scored riskier than 99% of active trials completed
• Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma NCT02278887 · started 2014 · scored riskier than 97% of active trials completed
• Vemurafenib and White Blood Cell Therapy for Advanced Melanoma NCT01585415 · started 2012 · scored riskier than 99% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.